PDL BioPharma to Participate at Cowen 39th Annual Health Care Conference

PDL BioPharma, Inc. (“PDL” or the “Company”) (NASDAQ: PDLI) announces that Dominique Monnet, PDL’s president and chief executive officer, and Peter Garcia, PDL’s chief financial officer, will present at the Cowen 39th Annual Health Care Conference in New York City.

INCLINE VILLAGE, Nev., /PRNewswire/ --PDL BioPharma, Inc., (“PDL” or the “Company”) (NASDAQ: PDLI) announces that Dominique Monnet, PDL’s president and chief executive officer, and Peter Garcia, PDL’s chief financial officer, will present at the Cowen 39th Annual Health Care Conference in New York City. The session will be webcast live and will occur on Tuesday, March 12, 2019, at 12:00 p.m. Eastern time (9:00 a.m. Pacific time).

To access the live and subsequently archived webcast of the presentation, visit the Company’s website at https://www.pdl.com/, go to the Investor Relations section and select “Events & Presentations.” Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. The archived webcast will be available for at least seven days following the presentation.

About PDL BioPharma, Inc.
PDL BioPharma seeks to provide a significant return for its stockholders through the acquisition, growth and potential monetization of a portfolio of actively managed pharmaceutical assets. PDL is pursuing the acquisition of pharmaceutical products and companies that have the potential of generating significant shareholder value. PDL is focused on commercial stage assets with multiple year revenue growth potential as well as late clinical stage pharmaceutical products. For more information please visit www.pdl.com

PDL BioPharma, Inc. (PRNewsFoto/PDL BioPharma, Inc.)

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-to-participate-at-cowen-39th-annual-health-care-conference-300806678.html

SOURCE PDL BioPharma, Inc.


Company Codes: NASDAQ-NMS:PDLI
MORE ON THIS TOPIC